Clinical Trial TitleEA6174: STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab: A phase III trial.
Clinical Trial Protocol Description:
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (American Joint Committee on Cancer [AJCC] version 8) I-IIIb.
- Have disease-free status documented by a complete physical examination and conventional imaging studies within 8 weeks prior to registration.
- Have no history of distant metastatic disease.
This is a partial list of inclusion and exclusion criteria.